Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib

Canadian Urological Association Journal

Volumn 8, Issue 3-4, 2014, Pages e121-e125

  Iacovelli, Roberto ^a   Cartenì, Giacomo ^b   Milella, Michele ^c   Berardi, Rossana ^d   Di Lorenzo, Giuseppe ^e   Verzoni, Elena ^f   Rizzo, Mimma ^b   Santoni, Matteo ^d   Procopio, Giuseppe ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897770793     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.1604     Document Type: Article

References (15)

1. Lam JS, Leppert JT, Belldegrun AS, et al. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12. http://dx.doi.org/10.1007/s00345-004-0466-0.
2. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112-25. http://dx.doi.org/10.3322/canjclin.57.2.112.
3. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006;6:729-34. http://dx.doi.org/10.1038/nrc1974.
4. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7. http://dx.doi.org/10.1038/nm1337.
5. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon-alpha, or both for advanced renal cell carcinoma. N Eng J Med 2007;356:2271-81. http://dx.doi.org/10.1056/NEJMoa066838.
6. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind randomized placebo controlled phase III trial. Lancet 2008;372:449-56. http://dx.doi.org/10.1016/S0140-6736(08)61039-9.
7. Chen CC, Hess GP, Liu Z, et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10:256-61. http://dx.doi.org/10.1016/j.clgc.2012.04.006.
8. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16. http://dx.doi.org/10.1093/jnci/92.3.205.
10. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256-65. http://dx.doi.org/10.1002/cncr.25219.
11. Bojanapally PR, Graham S, Rustine, et al. Temsirolimus for advanced renal cell carcinoma: compassionate versus commercial use. J Clin Oncol 2008;26(Suppl):abstr 16139.
12. Schmidinger M, Vogel UM, Lamm W, et al. Temsirolimus in heavily pre-treated patients with metastatic renal cell carcinoma: Preliminary results from the Austrian Compassionate Use Program. J Clin Oncol 2008;26(Suppl):abstr 16125.
13. Mackenzie MJ, Rini BI, Elson P, et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol 2011;22:145-8. http://dx.doi.org/10.1093/annonc/mdq320.
14. Milella M, Di Lorenzo G, Felici A, et al. Medical optimization of Torisel® (MOTOR): A phase II trial of temsirolimus as second-line treatment for advanced RCC by the Italian kidney cancer group (GIR). Ann Oncol 2012; 23(Suppl 9):abstract 846P.
15. Hutson T, Escudier B, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial. Ann Oncol 2012;23(Suppl 9):abstract LBA22 PR.